{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T10:59:33Z","timestamp":1773745173785,"version":"3.50.1"},"reference-count":120,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2011,2,11]],"date-time":"2011-02-11T00:00:00Z","timestamp":1297382400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Exp Metastasis"],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1007\/s10585-010-9368-2","type":"journal-article","created":{"date-parts":[[2011,2,10]],"date-time":"2011-02-10T06:25:59Z","timestamp":1297319159000},"page":"327-336","source":"Crossref","is-referenced-by-count":18,"title":["Genetic factors in metastatic progression of cutaneous melanoma: the future role of circulating melanoma cells in prognosis and management"],"prefix":"10.1007","volume":"28","author":[{"given":"A.","family":"Ireland","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Millward","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Pearce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Ziman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,2,11]]},"reference":[{"key":"9368_CR1","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1002\/cncr.21372","volume":"104","author":"TB Lewis","year":"2005","unstructured":"Lewis TB et al (2005) Molecular classification of melanoma using real-time quantitative reverse transcriptase-polymerase chain reaction. Cancer 104:1678\u20131686","journal-title":"Cancer"},{"key":"9368_CR2","unstructured":"Australasian Association of Cancer Registries (2006) Australian Institute of Health and Welfare. http:\/\/www.aihw.gov.au\/cancer\/aacr\/ . Cited 28\/4\/10"},{"key":"9368_CR3","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.suronc.2006.05.003","volume":"15","author":"A Jack","year":"2006","unstructured":"Jack A et al (2006) The treatment of melanoma with an emphasis on immunotherapeutic strategies. Surg Oncol 15:13\u201324","journal-title":"Surg Oncol"},{"key":"9368_CR4","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/CMR.0b013e328308fddb","volume":"18","author":"RT Lee","year":"2008","unstructured":"Lee RT et al (2008) Melanoma presenting as circulating tumor cells associated with failed angiogenesis. Melanoma Res 18:289\u2013294","journal-title":"Melanoma Res"},{"key":"9368_CR5","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1586\/17469872.3.5.569","volume":"3","author":"B Zbytek","year":"2008","unstructured":"Zbytek B et al (2008) Current concepts of metastasis in melanoma. Expert Rev Dermatol 3:569\u2013585","journal-title":"Expert Rev Dermatol"},{"key":"9368_CR6","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.hoc.2009.03.006","volume":"23","author":"AS Yang","year":"2009","unstructured":"Yang AS, Chapman PB (2009) The history and future of chemotherapy for melanoma. Hematol Oncol Clin North Am 23:583\u2013597","journal-title":"Hematol Oncol Clin North Am"},{"key":"9368_CR7","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1097\/00000658-197511000-00007","volume":"182","author":"A Breslow","year":"1975","unstructured":"Breslow A (1975) Tumor thickness, level of invasion and node dissection in stage I cutaneous melanoma. Ann Surg 182:572\u2013575","journal-title":"Ann Surg"},{"key":"9368_CR8","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1200\/JCO.2001.19.16.3635","volume":"19","author":"CM Balch","year":"2001","unstructured":"Balch CM et al (2001) Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19:3635\u20133648","journal-title":"J Clin Oncol"},{"key":"9368_CR9","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1200\/JCO.1998.16.3.1103","volume":"16","author":"O Eton","year":"1998","unstructured":"Eton O et al (1998) Prognostic factors for survival of patients treated systemically for disseminated melanoma. J Clin Oncol 16:1103\u20131111","journal-title":"J Clin Oncol"},{"key":"9368_CR10","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1245\/s10434-007-9717-9","volume":"15","author":"AB Francken","year":"2008","unstructured":"Francken AB et al (2008) Prognosis and determinants of outcome following locoregional or distant recurrence in patients with cutaneous melanoma. Ann Surg Oncol 15:1476\u20131484","journal-title":"Ann Surg Oncol"},{"key":"9368_CR11","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S0140-6736(09)61397-0","volume":"374","author":"JF Thompson","year":"2009","unstructured":"Thompson JF, Scolyer RA, Kefford RF (2009) Cutaneous melanoma in the era of molecular profiling. Lancet 374:362\u2013365","journal-title":"Lancet"},{"key":"9368_CR12","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1136\/bjo.2003.029058","volume":"88","author":"AD Singh","year":"2004","unstructured":"Singh AD et al (2004) The Zimmerman-McLean-Foster hypothesis: 25\u00a0years later. Br J Ophthalmol 88:962\u2013967","journal-title":"Br J Ophthalmol"},{"key":"9368_CR13","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.stem.2008.08.005","volume":"3","author":"RM White","year":"2008","unstructured":"White RM, Zon LI (2008) Melanocytes in development, regeneration, and cancer. Cell Stem Cell 3:242\u2013252","journal-title":"Cell Stem Cell"},{"key":"9368_CR14","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1046\/j.1365-2133.2001.04614.x","volume":"146","author":"DL Roberts","year":"2002","unstructured":"Roberts DL et al (2002) U.K. guidelines for the management of cutaneous melanoma. Br J Dermatol 146:7\u201317","journal-title":"Br J Dermatol"},{"key":"9368_CR15","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1038\/sj.bjc.6602848","volume":"93","author":"JS Michaelson","year":"2005","unstructured":"Michaelson JS et al (2005) Spread of human cancer cells occurs with probabilities indicative of a nongenetic mechanism. Br J Cancer 93:1244\u20131249","journal-title":"Br J Cancer"},{"key":"9368_CR16","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1200\/JCO.2003.06.110","volume":"21","author":"RA Wascher","year":"2003","unstructured":"Wascher RA et al (2003) Molecular tumor markers in the blood: early prediction of disease outcome in melanoma patients treated with a melanoma vaccine. J Clin Oncol 21:2558\u20132563","journal-title":"J Clin Oncol"},{"key":"9368_CR17","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1600-0749.2006.00322.x","volume":"19","author":"KS Hoek","year":"2006","unstructured":"Hoek KS et al (2006) Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigment Cell Res 19:290\u2013302","journal-title":"Pigment Cell Res"},{"key":"9368_CR18","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S1470-2045(07)70140-7","volume":"8","author":"M Bockhorn","year":"2007","unstructured":"Bockhorn M, Jain RK, Munn LL (2007) Active versus passive mechanisms in metastasis: do cancer cells crawl into vessels, or are they pushed? Lancet Oncol 8:444\u2013448","journal-title":"Lancet Oncol"},{"key":"9368_CR19","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/sj.bjc.6605214","volume":"101","author":"LL Chen","year":"2009","unstructured":"Chen LL et al (2009) Cancer metastasis networks and the prediction of progression patterns. Br J Cancer 101:749\u2013758","journal-title":"Br J Cancer"},{"key":"9368_CR20","first-page":"512","volume":"35","author":"TP Butler","year":"1975","unstructured":"Butler TP, Gullino PM (1975) Quantitation of cell shedding into efferent blood of mammary adenocarcinoma. Cancer Res 35:512\u2013516","journal-title":"Cancer Res"},{"key":"9368_CR21","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S1470-2045(01)00622-2","volume":"3","author":"IJ Fidler","year":"2002","unstructured":"Fidler IJ et al (2002) The seed and soil hypothesis: vascularisation and brain metastases. Lancet Oncol 3:53\u201357","journal-title":"Lancet Oncol"},{"key":"9368_CR22","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1056\/NEJMra0805239","volume":"359","author":"AC Chiang","year":"2008","unstructured":"Chiang AC, Massague J (2008) Molecular basis of metastasis. N Engl J Med 359:2814\u20132823","journal-title":"N Engl J Med"},{"key":"9368_CR23","doi-asserted-by":"crossref","first-page":"4469","DOI":"10.1158\/1078-0432.CCR-08-0012","volume":"14","author":"A Ulmer","year":"2008","unstructured":"Ulmer A et al (2008) Visualization of circulating melanoma cells in peripheral blood of patients with primary uveal melanoma. Clin Cancer Res 14:4469\u20134474","journal-title":"Clin Cancer Res"},{"key":"9368_CR24","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1158\/1078-0432.CCR-0424-03","volume":"10","author":"A Ulmer","year":"2004","unstructured":"Ulmer A et al (2004) Immunomagnetic enrichment, genomic characterization, and prognostic impact of circulating melanoma cells. Clin Cancer Res 10:531\u2013537","journal-title":"Clin Cancer Res"},{"key":"9368_CR25","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ccr.2007.12.003","volume":"13","author":"Y Husemann","year":"2008","unstructured":"Husemann Y et al (2008) Systemic spread is an early step in breast cancer. Cancer Cell 13:58\u201368","journal-title":"Cancer Cell"},{"key":"9368_CR26","doi-asserted-by":"crossref","first-page":"4605","DOI":"10.1158\/1078-0432.CCR-06-0823","volume":"12","author":"S Mocellin","year":"2006","unstructured":"Mocellin S et al (2006) The prognostic value of circulating tumor cells in patients with melanoma: a systematic review and meta-analysis. Clin Cancer Res 12:4605\u20134613","journal-title":"Clin Cancer Res"},{"key":"9368_CR27","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1093\/annonc\/mdf202","volume":"13","author":"I Sekine","year":"2002","unstructured":"Sekine I et al (2002) Relationship between objective responses in phase I trials and potential efficacy of non-specific cytotoxic investigational new drugs. Ann Oncol 13:1300\u20131306","journal-title":"Ann Oncol"},{"key":"9368_CR28","first-page":"488","volume":"23","author":"S Bhatia","year":"2009","unstructured":"Bhatia S, Tykodi SS, Thompson JA (2009) Treatment of metastatic melanoma: an overview. Oncol 23:488\u2013496","journal-title":"Oncol"},{"key":"9368_CR29","first-page":"CD001215","volume":"2","author":"Crosby T FR","year":"2000","unstructured":"T FR Crosby, Coles B, Mason M (2000) Systemic treatments for metastatic cutaneous melanoma. Cochrane Database Syst Rev 2:CD001215","journal-title":"Cochrane Database Syst Rev"},{"key":"9368_CR30","doi-asserted-by":"crossref","unstructured":"Richards JM BA, Gonzalez R, et al. (2005) High-dose Allovectin-7\u00ae in patients with advanced metastatic melanoma: final Phase 2 data and design of Phase 3 registration trial. J Clin Oncol 23:16s:7543","DOI":"10.1200\/jco.2005.23.16_suppl.7543"},{"key":"9368_CR31","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1007\/s11912-010-0095-2","volume":"12","author":"C Shepherd","year":"2010","unstructured":"Shepherd C, Puzanov I, Sosman JA (2010) B-RAF inhibitors: an evolving role in the therapy of malignant melanoma. Curr Oncol Rep 12:146\u2013152","journal-title":"Curr Oncol Rep"},{"key":"9368_CR32","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1755-148X.2009.00655.x","volume":"23","author":"DE Fisher","year":"2010","unstructured":"Fisher DE et al (2010) Melanoma from bench to bedside: meeting report from the 6th international melanoma congress. Pigment Cell Melanoma Res 23:14\u201326","journal-title":"Pigment Cell Melanoma Res"},{"key":"9368_CR33","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1097\/CAD.0b013e3283330590","volume":"20","author":"H Modjtahedi","year":"2009","unstructured":"Modjtahedi H, Essapen S (2009) Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities. Anticancer Drugs 20:851\u2013865","journal-title":"Anticancer Drugs"},{"key":"9368_CR34","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1002011","volume":"363","author":"KT Flaherty","year":"2010","unstructured":"Flaherty KT et al (2010) Inhibition of Mutated, Activated BRAF in Metastatic Melanoma. N Engl J Med 363:809\u2013819","journal-title":"N Engl J Med"},{"key":"9368_CR35","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.2174\/092986709788186192","volume":"16","author":"A Mazzocca","year":"2009","unstructured":"Mazzocca A, Carloni V (2009) The metastatic process: methodological advances and pharmacological challenges. Curr Med Chem 16:1704\u20131717","journal-title":"Curr Med Chem"},{"key":"9368_CR36","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/j.1600-0854.2006.00425.x","volume":"7","author":"K Bossche Van Den","year":"2006","unstructured":"Van Den Bossche K, Naeyaert JM, Lambert J (2006) The quest for the mechanism of melanin transfer. Traffic 7:769\u2013778","journal-title":"Traffic"},{"key":"9368_CR37","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1111\/j.1349-7006.2007.00550.x","volume":"98","author":"A Moustakas","year":"2007","unstructured":"Moustakas A, Heldin CH (2007) Signaling networks guiding epithelial-mesenchymal transitions during embryogenesis and cancer progression. Cancer Sci 98:1512\u20131520","journal-title":"Cancer Sci"},{"key":"9368_CR38","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.canlet.2006.12.014","volume":"253","author":"P Paterlini-Brechot","year":"2007","unstructured":"Paterlini-Brechot P, Benali NL (2007) Circulating tumor cells (CTC) detection: clinical impact and future directions. Cancer Lett 253:180\u2013204","journal-title":"Cancer Lett"},{"key":"9368_CR39","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nature04871","volume":"441","author":"J Pouyssegur","year":"2006","unstructured":"Pouyssegur J, Dayan F, Mazure NM (2006) Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 441:437\u2013443","journal-title":"Nature"},{"key":"9368_CR40","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1046\/j.1365-2133.2001.04336.x","volume":"145","author":"T Kageshita","year":"2001","unstructured":"Kageshita T et al (2001) Loss of beta-catenin expression associated with disease progression in malignant melanoma. Br J Dermatol 145:210\u2013216","journal-title":"Br J Dermatol"},{"key":"9368_CR41","doi-asserted-by":"crossref","first-page":"4901","DOI":"10.1242\/jcs.02594","volume":"118","author":"R Vogelmann","year":"2005","unstructured":"Vogelmann R et al (2005) TGFbeta-induced downregulation of E-cadherin-based cell-cell adhesion depends on PI3-kinase and PTEN. J Cell Sci 118:4901\u20134912","journal-title":"J Cell Sci"},{"key":"9368_CR42","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1387\/ijdb.041794hp","volume":"48","author":"H Peinado","year":"2004","unstructured":"Peinado H, Portillo F, Cano A (2004) Transcriptional regulation of cadherins during development and carcinogenesis. Int J Dev Biol 48:365\u2013375","journal-title":"Int J Dev Biol"},{"key":"9368_CR43","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/S0002-9440(10)65023-7","volume":"156","author":"MY Hsu","year":"2000","unstructured":"Hsu MY et al (2000) E-cadherin expression in melanoma cells restores keratinocyte-mediated growth control and down-regulates expression of invasion-related adhesion receptors. Am J Pathol 156:1515\u20131525","journal-title":"Am J Pathol"},{"key":"9368_CR44","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.cell.2008.09.043","volume":"135","author":"V Sanz-Moreno","year":"2008","unstructured":"Sanz-Moreno V et al (2008) Rac activation and inactivation control plasticity of tumor cell movement. Cell 135:510\u2013523","journal-title":"Cell"},{"key":"9368_CR45","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/nrc745","volume":"2","author":"M Egeblad","year":"2002","unstructured":"Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2:161\u2013174","journal-title":"Nat Rev Cancer"},{"key":"9368_CR46","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1158\/0008-5472.CAN-05-4005","volume":"66","author":"CE Lewis","year":"2006","unstructured":"Lewis CE, Pollard JW (2006) Distinct role of macrophages in different tumor microenvironments. Cancer Res 66:605\u2013612","journal-title":"Cancer Res"},{"key":"9368_CR47","first-page":"997","volume":"34","author":"LA Liotta","year":"1974","unstructured":"Liotta LA, Kleinerman J, Saidel GM (1974) Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. Cancer Res 34:997\u20131004","journal-title":"Cancer Res"},{"key":"9368_CR48","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S1040-8428(97)00234-5","volume":"25","author":"GV Glinsky","year":"1997","unstructured":"Glinsky GV (1997) Apoptosis in metastatic cancer cells. Crit Rev Oncol Hematol 25:175\u2013186","journal-title":"Crit Rev Oncol Hematol"},{"key":"9368_CR49","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/sj.bjc.6690760","volume":"81","author":"MA Swartz","year":"1999","unstructured":"Swartz MA et al (1999) Cells shed from tumours show reduced clonogenicity, resistance to apoptosis, and in vivo tumorigenicity. Br J Cancer 81:756\u2013759","journal-title":"Br J Cancer"},{"key":"9368_CR50","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/cyto.a.20073","volume":"62","author":"CJ Larson","year":"2004","unstructured":"Larson CJ et al (2004) Apoptosis of circulating tumor cells in prostate cancer patients. Cytometry A 62:46\u201353","journal-title":"Cytometry A"},{"key":"9368_CR51","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0002-9440(10)61667-7","volume":"159","author":"G Mehes","year":"2001","unstructured":"Mehes G et al (2001) Circulating breast cancer cells are frequently apoptotic. Am J Pathol 159:17\u201320","journal-title":"Am J Pathol"},{"key":"9368_CR52","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/nm0295-149","volume":"1","author":"L Holmgren","year":"1995","unstructured":"Holmgren L, O\u2019Reilly MS, Folkman J (1995) Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1:149\u2013153","journal-title":"Nat Med"},{"key":"9368_CR53","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/nrc2622","volume":"9","author":"DX Nguyen","year":"2009","unstructured":"Nguyen DX, Bos PD, Massague J (2009) Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 9:274\u2013284","journal-title":"Nat Rev Cancer"},{"key":"9368_CR54","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1073\/pnas.261704098","volume":"99","author":"L Borsig","year":"2002","unstructured":"Borsig L et al (2002) Synergistic effects of L- and P-selectin in facilitating tumor metastasis can involve non-mucin ligands and implicate leukocytes as enhancers of metastasis. Proc Natl Acad Sci USA 99:2193\u20132198","journal-title":"Proc Natl Acad Sci USA"},{"key":"9368_CR55","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1158\/0008-5472.CAN-05-3121","volume":"66","author":"H Laubli","year":"2006","unstructured":"Laubli H et al (2006) L-selectin facilitation of metastasis involves temporal induction of Fut7-dependent ligands at sites of tumor cell arrest. Cancer Res 66:1536\u20131542","journal-title":"Cancer Res"},{"key":"9368_CR56","doi-asserted-by":"crossref","first-page":"4606","DOI":"10.4049\/jimmunol.180.7.4606","volume":"180","author":"MB Fuertes","year":"2008","unstructured":"Fuertes MB et al (2008) Intracellular retention of the NKG2D ligand MHC class I chain-related gene A in human melanomas confers immune privilege and prevents NK cell-mediated cytotoxicity. J Immunol 180:4606\u20134614","journal-title":"J Immunol"},{"key":"9368_CR57","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/sj.onc.1209844","volume":"26","author":"A Lacreusette","year":"2007","unstructured":"Lacreusette A et al (2007) Loss of oncostatin M receptor beta in metastatic melanoma cells. Oncogene 26:881\u2013892","journal-title":"Oncogene"},{"key":"9368_CR58","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/j.1600-0463.2008.01027.x","volume":"116","author":"CE Horak","year":"2008","unstructured":"Horak CE et al (2008) The role of metastasis suppressor genes in metastatic dormancy. APMIS 116:586\u2013601","journal-title":"APMIS"},{"key":"9368_CR59","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1172\/JCI42002","volume":"120","author":"J Eyles","year":"2010","unstructured":"Eyles J et al (2010) Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma. J Clin Invest 120:2030\u20132039","journal-title":"J Clin Invest"},{"key":"9368_CR60","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1093\/jnci\/92.21.1717","volume":"92","author":"BA Yoshida","year":"2000","unstructured":"Yoshida BA et al (2000) Metastasis-suppressor genes: a review and perspective on an emerging field. J Natl Cancer Inst 92:1717\u20131730","journal-title":"J Natl Cancer Inst"},{"key":"9368_CR61","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1172\/JCI43424","volume":"120","author":"M R\u00f6cken","year":"2010","unstructured":"R\u00f6cken M (2010) Early tumor dissemination, but late metastasis: insights into tumor dormancy. J Clin Invest 120:1800\u20131803","journal-title":"J Clin Invest"},{"key":"9368_CR62","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1023\/A:1022530100931","volume":"20","author":"JF Harms","year":"2003","unstructured":"Harms JF, Welch DR, Miele ME (2003) KISS1 metastasis suppression and emergent pathways. Clin Exp Metastasis 20:11\u201318","journal-title":"Clin Exp Metastasis"},{"key":"9368_CR63","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1051\/medsci\/200723121115","volume":"23","author":"M Boissan","year":"2007","unstructured":"Boissan M, Poupon MF, Lacombe ML (2007) NM23 and metastasis suppressor genes: update. Med Sci (Paris) 23:1115\u20131123","journal-title":"Med Sci (Paris)"},{"key":"9368_CR64","doi-asserted-by":"crossref","first-page":"5006","DOI":"10.1158\/1078-0432.CCR-08-0238","volume":"14","author":"PS Steeg","year":"2008","unstructured":"Steeg PS, Horak CE, Miller KD (2008) Clinical-translational approaches to the Nm23\u2013H1 metastasis suppressor. Clin Cancer Res 14:5006\u20135012","journal-title":"Clin Cancer Res"},{"key":"9368_CR65","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1101\/gad.1714608","volume":"22","author":"S Gobeil","year":"2008","unstructured":"Gobeil S et al (2008) A genome-wide shRNA screen identifies GAS1 as a novel melanoma metastasis suppressor gene. Genes Dev 22:2932\u20132940","journal-title":"Genes Dev"},{"key":"9368_CR66","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1006\/excr.2001.5452","volume":"273","author":"LA Shevde","year":"2002","unstructured":"Shevde LA et al (2002) Suppression of human melanoma metastasis by the metastasis suppressor gene, BRMS1. Exp Cell Res 273:229\u2013239","journal-title":"Exp Cell Res"},{"key":"9368_CR67","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1200\/JCO.2007.14.0285","volume":"26","author":"CC Lee","year":"2008","unstructured":"Lee CC et al (2008) Improved survival after lymphadenectomy for nodal metastasis from an unknown primary melanoma. J Clin Oncol 26:535\u2013541","journal-title":"J Clin Oncol"},{"key":"9368_CR68","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1023\/A:1008201931959","volume":"9","author":"G Vijuk","year":"1998","unstructured":"Vijuk G, Coates AS (1998) Survival of patients with visceral metastatic melanoma from an occult primary lesion: a retrospective matched cohort study. Ann Oncol 9:419\u2013422","journal-title":"Ann Oncol"},{"key":"9368_CR69","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1046\/j.1365-2133.2003.05155.x","volume":"148","author":"I Zalaudek","year":"2003","unstructured":"Zalaudek I et al (2003) Local recurrence in melanoma in situ: influence of sex, age, site of involvement and therapeutic modalities. Br J Dermatol 148:703\u2013708","journal-title":"Br J Dermatol"},{"key":"9368_CR70","doi-asserted-by":"crossref","first-page":"8057","DOI":"10.1200\/JCO.2005.02.0958","volume":"23","author":"K Koyanagi","year":"2005","unstructured":"Koyanagi K et al (2005) Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial. J Clin Oncol 23:8057\u20138064","journal-title":"J Clin Oncol"},{"key":"9368_CR71","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1167\/iovs.03-0538","volume":"44","author":"E Kujala","year":"2003","unstructured":"Kujala E, M\u00e4kitie T, Kivel\u00e4 T (2003) Very long-term prognosis of patients with malignant uveal melanoma. Investig Ophthalmol Vis Sci 44:4651\u20134659","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"9368_CR72","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.hoc.2009.03.002","volume":"23","author":"JA Wargo","year":"2009","unstructured":"Wargo JA, Tanabe K (2009) Surgical management of melanoma. Hematol Oncol Clin North Am 23:565\u2013581","journal-title":"Hematol Oncol Clin North Am"},{"key":"9368_CR73","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/ng1060","volume":"33","author":"S Ramaswamy","year":"2003","unstructured":"Ramaswamy S et al (2003) A molecular signature of metastasis in primary solid tumors. Nat Genet 33:49\u201354","journal-title":"Nat Genet"},{"key":"9368_CR74","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/418823a","volume":"418","author":"R Bernards","year":"2002","unstructured":"Bernards R, Weinberg RA (2002) A progression puzzle. Nature 418:823","journal-title":"Nature"},{"key":"9368_CR75","first-page":"6109","volume":"48","author":"C Waghorne","year":"1988","unstructured":"Waghorne C et al (1988) Genetic evidence for progressive selection and overgrowth of primary tumors by metastatic cell subpopulations. Cancer Res 48:6109\u20136114","journal-title":"Cancer Res"},{"key":"9368_CR76","doi-asserted-by":"crossref","first-page":"9328","DOI":"10.1158\/0008-5472.CAN-05-1343","volume":"65","author":"D Fang","year":"2005","unstructured":"Fang D et al (2005) A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 65:9328\u20139337","journal-title":"Cancer Res"},{"key":"9368_CR77","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/sj.jid.5700017","volume":"126","author":"JM Grichnik","year":"2006","unstructured":"Grichnik JM et al (2006) Melanoma, a tumor based on a mutant stem cell? J Invest Dermatol 126:142\u2013153","journal-title":"J Invest Dermatol"},{"key":"9368_CR78","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.ejca.2007.01.017","volume":"43","author":"E Monzani","year":"2007","unstructured":"Monzani E et al (2007) Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur J Cancer 43:935\u2013946","journal-title":"Eur J Cancer"},{"key":"9368_CR79","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nature06489","volume":"451","author":"T Schatton","year":"2008","unstructured":"Schatton T et al (2008) Identification of cells initiating human melanomas. Nature 451:345\u2013349","journal-title":"Nature"},{"key":"9368_CR80","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1200\/JCO.2007.15.5465","volume":"26","author":"SE Zabierowski","year":"2008","unstructured":"Zabierowski SE, Herlyn M (2008) Melanoma stem cells: the dark seed of melanoma. J Clin Oncol 26:2890\u20132894","journal-title":"J Clin Oncol"},{"key":"9368_CR81","doi-asserted-by":"crossref","first-page":"5606","DOI":"10.1158\/1078-0432.CCR-06-1537","volume":"12","author":"MS Wicha","year":"2006","unstructured":"Wicha MS (2006) Cancer stem cells and metastasis: lethal seeds. Clin Cancer Res 12:5606\u20135607","journal-title":"Clin Cancer Res"},{"key":"9368_CR82","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/nrclinonc.2009.44","volume":"6","author":"K Pantel","year":"2009","unstructured":"Pantel K, Alix-Panabieres C, Riethdorf S (2009) Cancer micrometastases. Nat Rev Clin Oncol 6:339\u2013351","journal-title":"Nat Rev Clin Oncol"},{"key":"9368_CR83","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.bbrc.2008.02.022","volume":"368","author":"GI Keshet","year":"2008","unstructured":"Keshet GI et al (2008) MDR1 expression identifies human melanoma stem cells. Biochem Biophys Res Commun 368:930\u2013936","journal-title":"Biochem Biophys Res Commun"},{"key":"9368_CR84","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1755-148X.2007.00427.x","volume":"21","author":"T Schatton","year":"2008","unstructured":"Schatton T, Frank MH (2008) Cancer stem cells and human malignant melanoma. Pigment Cell Melanoma Res 21:39\u201355","journal-title":"Pigment Cell Melanoma Res"},{"key":"9368_CR85","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1002\/ijc.24129","volume":"124","author":"KS Smalley","year":"2009","unstructured":"Smalley KS, Herlyn M (2009) Integrating tumor-initiating cells into the paradigm for melanoma targeted therapy. Int J Cancer 124:1245\u20131250","journal-title":"Int J Cancer"},{"key":"9368_CR86","doi-asserted-by":"crossref","first-page":"228","DOI":"10.4161\/cbt.5.2.2510","volume":"5","author":"AR Hess","year":"2006","unstructured":"Hess AR, Seftor EA, Gruman LM, Kinch MS, Seftor RE, Hendrix MJ (2006) VE-cadherin regulates EphA2 in aggressive melanoma cells through a novel signaling pathway: implications for vasculogenic mimicry. Cancer Biol Ther 5:228\u2013233","journal-title":"Cancer Biol Ther"},{"key":"9368_CR87","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s12015-008-9048-7","volume":"5","author":"C La Porta","year":"2009","unstructured":"La Porta C (2009) Cancer stem cells: lessons from melanoma. Stem Cell Rev 5:61\u201365","journal-title":"Stem Cell Rev"},{"key":"9368_CR88","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.cell.2010.04.020","volume":"141","author":"A Roesch","year":"2010","unstructured":"Roesch A et al (2010) A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 141:583\u2013594","journal-title":"Cell"},{"key":"9368_CR89","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/j.1755-148X.2010.00757.x","volume":"23","author":"KS Hoek","year":"2010","unstructured":"Hoek KS, Goding CR (2010) Cancer stem cells versus phenotype-switching in melanoma. Pigment Cell Melanoma Res 23:746\u2013759","journal-title":"Pigment Cell Melanoma Res"},{"key":"9368_CR90","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1755-148X.2007.00433.x","volume":"21","author":"DC Bennett","year":"2008","unstructured":"Bennett DC (2008) How to make a melanoma: what do we know of the primary clonal events? Pigment Cell Melanoma Res 21:27\u201338","journal-title":"Pigment Cell Melanoma Res"},{"key":"9368_CR91","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.cca.2005.10.029","volume":"367","author":"AK Bosserhoff","year":"2006","unstructured":"Bosserhoff AK (2006) Novel biomarkers in malignant melanoma. Clin Chim Acta 367:28\u201335","journal-title":"Clin Chim Acta"},{"issue":"Suppl 6","key":"9368_CR92","doi-asserted-by":"crossref","first-page":"vi8","DOI":"10.1093\/annonc\/mdp251","volume":"20","author":"H Gogas","year":"2009","unstructured":"Gogas H et al (2009) Biomarkers in melanoma. Ann Oncol 20(Suppl 6):vi8\u2013vi13","journal-title":"Ann Oncol"},{"key":"9368_CR93","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/j.1600-0749.2006.00356.x","volume":"20","author":"S Medic","year":"2007","unstructured":"Medic S et al (2007) Molecular markers of circulating melanoma cells. Pigment Cell Res 20:80\u201391","journal-title":"Pigment Cell Res"},{"key":"9368_CR94","doi-asserted-by":"crossref","first-page":"6111","DOI":"10.1158\/0008-5472.CAN-05-4198","volume":"66","author":"K Koyanagi","year":"2006","unstructured":"Koyanagi K et al (2006) Association of circulating tumor cells with serum tumor-related methylated DNA in peripheral blood of melanoma patients. Cancer Res 66:6111\u20136117","journal-title":"Cancer Res"},{"key":"9368_CR95","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1373\/clinchem.2006.081828","volume":"53","author":"L Xi","year":"2007","unstructured":"Xi L et al (2007) Optimal markers for real-time quantitative reverse transcription PCR detection of circulating tumor cells from melanoma, breast, colon, esophageal, head and neck, and lung cancers. Clin Chem 53:1206\u20131215","journal-title":"Clin Chem"},{"key":"9368_CR96","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1158\/1078-0432.CCR-05-1847","volume":"12","author":"K Koyanagi","year":"2006","unstructured":"Koyanagi K et al (2006) Microphthalmia transcription factor as a molecular marker for circulating tumor cell detection in blood of melanoma patients. Clin Cancer Res 12:1137\u20131143","journal-title":"Clin Cancer Res"},{"key":"9368_CR97","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1158\/0008-5472.CAN-06-3481","volume":"67","author":"SR Alonso","year":"2007","unstructured":"Alonso SR et al (2007) A high-throughput study in melanoma identifies epithelial-mesenchymal transition as a major determinant of metastasis. Cancer Res 67:3450\u20133460","journal-title":"Cancer Res"},{"key":"9368_CR98","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1479-5876-4-50","volume":"4","author":"S Mandruzzato","year":"2006","unstructured":"Mandruzzato S et al (2006) A gene expression signature associated with survival in metastatic melanoma. J Transl Med 4:50","journal-title":"J Transl Med"},{"key":"9368_CR99","doi-asserted-by":"crossref","first-page":"7234","DOI":"10.1158\/1078-0432.CCR-05-0683","volume":"11","author":"D Talantov","year":"2005","unstructured":"Talantov D et al (2005) Novel genes associated with malignant melanoma but not benign melanocytic lesions. Clin Cancer Res 11:7234\u20137242","journal-title":"Clin Cancer Res"},{"key":"9368_CR100","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1111\/j.1365-2133.2007.08246.x","volume":"157","author":"MG Tucci","year":"2007","unstructured":"Tucci MG et al (2007) Involvement of E-cadherin, beta-catenin, Cdc42 and CXCR4 in the progression and prognosis of cutaneous melanoma. Br J Dermatol 157:1212\u20131216","journal-title":"Br J Dermatol"},{"key":"9368_CR101","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/sj.onc.1210700","volume":"27","author":"A Kauffmann","year":"2008","unstructured":"Kauffmann A et al (2008) High expression of DNA repair pathways is associated with metastasis in melanoma patients. Oncogene 27:565\u2013573","journal-title":"Oncogene"},{"key":"9368_CR102","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1093\/jnci\/djj103","volume":"98","author":"V Winnepenninckx","year":"2006","unstructured":"Winnepenninckx V et al (2006) Gene expression profiling of primary cutaneous melanoma and clinical outcome. J Natl Cancer Inst 98:472\u2013482","journal-title":"J Natl Cancer Inst"},{"key":"9368_CR103","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0625.2007.00655.x","volume":"17","author":"J Eberle","year":"2008","unstructured":"Eberle J et al (2008) Apoptosis pathways and oncolytic adenoviral vectors: promising targets and tools to overcome therapy resistance of malignant melanoma. Exp Dermatol 17:1\u201311","journal-title":"Exp Dermatol"},{"key":"9368_CR104","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1080\/10409230902755056","volume":"44","author":"S Medic","year":"2009","unstructured":"Medic S, Ziman M (2009) PAX3 across the spectrum: from melanoblast to melanoma. Crit Rev Biochem Mol Biol 44:85\u201397","journal-title":"Crit Rev Biochem Mol Biol"},{"key":"9368_CR105","doi-asserted-by":"crossref","first-page":"4018","DOI":"10.1158\/0008-5472.CAN-07-6334","volume":"68","author":"JM Adams","year":"2008","unstructured":"Adams JM, Strasser A (2008) Is tumor growth sustained by rare cancer stem cells or dominant clones? Cancer Res 68:4018\u20134021","journal-title":"Cancer Res"},{"key":"9368_CR106","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.1101\/gad.406406","volume":"20","author":"S Carreira","year":"2006","unstructured":"Carreira S et al (2006) Mitf regulation of Dia1 controls melanoma proliferation and invasiveness. Genes Dev 20:3426\u20133439","journal-title":"Genes Dev"},{"key":"9368_CR107","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1101\/sqb.2005.70.033","volume":"70","author":"PB Gupta","year":"2005","unstructured":"Gupta PB et al (2005) The evolving portrait of cancer metastasis. Cold Spring Harb Symp Quant Biol 70:291\u2013297","journal-title":"Cold Spring Harb Symp Quant Biol"},{"key":"9368_CR108","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1111\/j.1365-2133.2005.06454.x","volume":"152","author":"L McArdle","year":"2005","unstructured":"McArdle L et al (2005) Microarray analysis of phosphatase gene expression in human melanoma. Br J Dermatol 152:925\u2013930","journal-title":"Br J Dermatol"},{"key":"9368_CR109","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/nm1448","volume":"12","author":"JM Topczewska","year":"2006","unstructured":"Topczewska JM et al (2006) Embryonic and tumorigenic pathways converge via Nodal signaling: role in melanoma aggressiveness. Nat Med 12:925\u2013932","journal-title":"Nat Med"},{"key":"9368_CR110","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/j.1755-148X.2008.00514.x","volume":"21","author":"JD Kubic","year":"2008","unstructured":"Kubic JD et al (2008) Pigmentation PAX-ways: the role of Pax3 in melanogenesis, melanocyte stem cell maintenance, and disease. Pigment Cell Melanoma Res 21:627\u2013645","journal-title":"Pigment Cell Melanoma Res"},{"key":"9368_CR111","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1038\/nature03292","volume":"433","author":"D Lang","year":"2005","unstructured":"Lang D et al (2005) Pax3 functions at a nodal point in melanocyte stem cell differentiation. Nature 433:884\u2013887","journal-title":"Nature"},{"key":"9368_CR112","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/modpathol.3801019","volume":"21","author":"RS Plummer","year":"2008","unstructured":"Plummer RS et al (2008) PAX3 expression in primary melanomas and nevi. Mod Pathol 21:525\u2013530","journal-title":"Mod Pathol"},{"key":"9368_CR113","doi-asserted-by":"crossref","first-page":"8152","DOI":"10.1158\/1078-0432.CCR-04-1110","volume":"10","author":"S Meng","year":"2004","unstructured":"Meng S et al (2004) Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res 10:8152\u20138162","journal-title":"Clin Cancer Res"},{"key":"9368_CR114","first-page":"50","volume":"14","author":"JJ Cools-Lartigue","year":"2008","unstructured":"Cools-Lartigue JJ et al (2008) Immunomagnetic isolation and in vitro expansion of human uveal melanoma cell lines. Mol Vis 14:50\u201355","journal-title":"Mol Vis"},{"key":"9368_CR115","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/nature07567","volume":"456","author":"E Quintana","year":"2008","unstructured":"Quintana E et al (2008) Efficient tumour formation by single human melanoma cells. Nature 456:593\u2013598","journal-title":"Nature"},{"key":"9368_CR116","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s10637-007-9080-5","volume":"26","author":"KD Lewis","year":"2008","unstructured":"Lewis KD et al (2008) A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma. Invest New Drugs 26:89\u201394","journal-title":"Invest New Drugs"},{"key":"9368_CR117","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s10549-008-0143-x","volume":"115","author":"M Tewes","year":"2009","unstructured":"Tewes M et al (2009) Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies. Breast Cancer Res Treat 115:581\u2013590","journal-title":"Breast Cancer Res Treat"},{"issue":"Suppl 1","key":"9368_CR118","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1186\/bcr1869","volume":"10","author":"T Fehm","year":"2008","unstructured":"Fehm T et al (2008) Micrometastatic spread in breast cancer: detection, molecular characterization and clinical relevance. Breast Cancer Res 10(Suppl 1):S1","journal-title":"Breast Cancer Res"},{"key":"9368_CR119","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1056\/NEJMoa040766","volume":"351","author":"M Cristofanilli","year":"2004","unstructured":"Cristofanilli M et al (2004) Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351:781\u2013791","journal-title":"N Engl J Med"},{"key":"9368_CR120","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s11864-007-0018-0","volume":"8","author":"S Dawood","year":"2007","unstructured":"Dawood S, Cristofanilli M (2007) Integrating circulating tumor cell assays into the management of breast cancer. Curr Treatment Options Oncol 8:89\u201395","journal-title":"Curr Treatment Options Oncol"}],"container-title":["Clinical & Experimental Metastasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-010-9368-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10585-010-9368-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-010-9368-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,8]],"date-time":"2019-06-08T12:48:06Z","timestamp":1559998086000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10585-010-9368-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2,11]]},"references-count":120,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["9368"],"URL":"https:\/\/doi.org\/10.1007\/s10585-010-9368-2","relation":{},"ISSN":["0262-0898","1573-7276"],"issn-type":[{"value":"0262-0898","type":"print"},{"value":"1573-7276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,2,11]]}}}